Highland Therapeutics

46 articles about Highland Therapeutics

• Highland Therapeutics Announces Appointment of Stephanie C. Read as President/CEO, Changes to Board of Directors

  4/27/2022

  Highland Therapeutics Inc. today announced the appointment of Stephanie C. Read as President/Chief Executive Officer, the appointment of Scott Myers as Chair of the Board and the additions of Kevin Bain and Ildiko Mehes as independent members of the Board of Directors.

• Highland Therapeutics Announces Appointment of Stephanie C. Read to Board of Directors

  12/9/2020

  Highland Therapeutics Inc. (“Highland”) today announced the appointment of Stephanie C. Read to its Board of Directors, effective November 13, 2020. Ms. Read brings to the Company a wealth of experience and expertise gained from over twenty years of tenure in the pharmaceuticals industry, including in the ADHD market. “It is my pleasure to welcome Ms. Read, an accomplished executive, to the Highland Board of Directors,” said

• Highland Therapeutics Announces New Chief Commercial Officer and Appointment of Chief Scientific Officer

  9/17/2020

  Highland Therapeutics Inc. (“Highland”) today announced two executive appointments at its wholly owned subsidiaries. Mr. Danny Villeneuve has assumed the role of Executive Vice President and Chief Commercial Officer and Dr. Bev Incledon has been promoted to the role of Executive Vice President and Chief

• 

  Is the ADHD Market Ready for a Disruptor? An Interview with Highland Therapeutics’ David Lickrish

  7/12/2019

  David Lickrish took time to speak with BioSpace about the companies’ new drug, Jornay PM (methylphenidate HCL Extended-Release CLL Capsules), and how it fits into the overall ADHD therapeutic market.

• ADDING MULTIMEDIA Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the Evening

  6/18/2019

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention Deficit Hyperactivity Disorder (“ADHD”), today announced that JORNAY PM™ (methylphenidate HCl) extended-release capsules CII is now available in the United States.

• Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the Evening

  6/11/2019

  Novel Drug Delivery Technology Offers Hope to Families Struggling Through Morning Routines

• Ironshore to Present Three Posters at the 2019 Annual American Professional Society of ADHD and Related Disorders (APSARD) Meeting

  1/10/2019

  JORNAY PM is expected to be available commercially in the first half of this year.

• Ironshore to Present New Data at The 65TH Annual AACAP Meeting

  10/17/2018

  The AACAP meeting will take place in Seattle, WA, October 22-27, 2018.

• Ironshore Pharmaceuticals Announces Appointment of W. Scott Evangelista as President and Chief Operating Officer

  9/6/2018

  Prior to joining Ironshore, Mr. Evangelista was President of Integrated Engagement Services at Quintiles

• Ironshore Pharmaceuticals Announces FDA Approval of JORNAY PMTM (Methylphenidate) Extended-Release Capsules CII for the Treatment of ADHD

  8/9/2018

  JORNAY PM approved for the treatment of ADHD in patients 6 years and older

• Highland Therapeutics’ ADHD Drug Hit With Delay, Company Still in Discussions With FDA

  8/3/2017

• Highland Therapeutics Announces Initiation Of Phase II Trial For HLD100 In Pediatric ADHD Patients

  8/26/2016

• Highland Therapeutics Announces Initiation Of Phase II Trial For HLD100 In Pediatric ADHD Patients

  8/25/2016

• Highland Therapeutics Announces Positive Data From Second Pivotal ADHD Trial For HLD-200

  6/6/2016

• Highland Therapeutics Announces Expansion Of Pipeline Into Inflammatory Bowel Disease

  5/26/2016

• Highland Therapeutics Announces Appointment Of Craig S. Lewis As President

  5/12/2016

• Highland Therapeutics Announces Positive Pivotal ADHD Trial Results For Its Investigational Drug Candidate Benjorna

  4/5/2016

• Highland Therapeutics Announces Trade Name Benjorna™ For Its Next-Generation ADHD Medicine

  3/30/2016

• Highland Therapeutics To Present At HighTech Business Decisions Healthcare Conference

  11/24/2015

• Highland Therapeutics To Present Data At Prestigious Scientific Meetings

  10/2/2015